Redefining Treatment Approaches in Advanced HCC

EP. 1: Management Challenges of Advanced HCC

February 25th 2021

Richard S. Finn, MD, leads a panel of experts in a discussion around key updates from the 2021 ASCO GI virtual meeting, and a review of the rapidly evolving landscape for unresectable advanced hepatocellular carcinoma.

EP. 2: Practical Considerations of TACE in HCC

February 25th 2021

A panel of experts discuss practical considerations for TACE in patients with unresectable BCLC stage B HCC, as well as define TACE-refractoriness and what to do if a patient fails treatment.

EP. 3: Recent Findings in Systemic Therapy for Patients With BCLC Stage B HCC 

March 5th 2021

Amit G. Singal, MD, MS, leads a review of recent data around the outcomes of systemic therapy for patients with BCLC stage B HCC.

EP. 4: TACE and Systemic Therapy in HCC

March 5th 2021

An in-depth discussion about the role of TACE in combination with systemic therapies for the treatment of HCC.

EP. 5: Combination Therapy for HCC Treatment

March 11th 2021

Experts discuss recent data surrounding emerging combinations of TACE plus systemic therapies for patients with BCLC stage B or C HCC.

EP. 6: A New Standard of Care for Liver Cancer Treatment

March 11th 2021

A discussion about the recent data from trials that looked at atezolizumab-bevacizumab for the treatment of advanced HCC, and its role as the new standard of care.

EP. 7: Personal Experience Using Atezolizumab-Bevacizumab in HCC Treatment

March 18th 2021

Laura M. Kulik, MD, leads a discussion about personal experiences using atezolizumab-bevacizumab and whether clinical trial data reflect real-world experience.

EP. 8: Considerations for Later Lines of Therapy in HCC Treatment

March 18th 2021

Experts in the field of HCC consider second and third lines of therapy after a patient’s disease state progresses after frontline atezolizumab-bevacizumab.

EP. 9: Treatment Strategies for Childs-Pugh B Disease

March 25th 2021

Experts expand on treatment strategies and sequencing approaches used for Child-Pugh B liver disease.

EP. 10: Role of TKIs in HCC Treatment

March 25th 2021

An examination of the use of second-line therapies after atezolizumab-bevacizumab, and the role of TKIs for the treatment of advanced HCC.

EP. 11: Ongoing Data for First-line Combinations in HCC

April 1st 2021

A summary of updates that explore ongoing data from various frontline combinations in unresectable HCC.

EP. 12: HCC Treatment: Emerging Data in IO Combinations

April 1st 2021

Experts discuss emerging data in immunotherapy combination approaches for the treatment of advanced HCC.

EP. 13: Role of Single Agent IO in Hepatocellular Carcinoma Frontline Therapies

April 8th 2021

A summary of ongoing clinical data that explore the use of frontline single agent immunotherapy in advanced HCC.

EP. 14: Challenges of Sequencing and Biomarkers in Hepatocellular Carcinoma

April 8th 2021

Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.

EP. 15: Final Thoughts on the Future of Liver Cancer

April 8th 2021

A panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.

x